Floatz logo

es014

Advanced Solid Tumor

Cancer Institute and Hospital, Chinese Academy of Medical Sciencesmonoclonal_antibodyPhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumor cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

es014 is also rated in:

Locally Advanced Solid TumorDormant
CC
Indicative ·
41 / 100
View asset →
Metastatic Solid TumorDormant
C
Indicative ·
37 / 100
View asset →
neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →